Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Kazuyoshi Ohkawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9700-2472; OpenAlex author ID A5066716330. Sources: OpenAlex.

Their work

Papers
36 (first author 2, last author 21)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 3 papers · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 6 papers · 2023: 4 papers · 2024: 4 papers · 2025: 4 papers · 2026: 7 papers

Papers 36

  1. Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment. Last author DOI 10.1002/cnr2.70492↗
  2. Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic C… Last author DOI 10.1002/cnr2.70691↗
  3. Effects of Pancreatic Duct Stenting on Nutrition and Pancreatic Function in Unresectable Pancreatic Cancer: A Pilot Study. Last author DOI 10.1002/jgh3.70358↗
  4. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… Last author DOI 10.1007/s10147-026-03071-6↗
  5. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
  6. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  7. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  8. Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. Last author DOI 10.1007/s12029-025-01309-6↗
  9. Impact of zinc deficiency on the prognosis of unresectable pancreatic cancer. Last author DOI 10.1016/j.pan.2025.05.007↗
  10. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Co-author DOI 10.1186/s12876-025-04108-2↗
  11. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  12. Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. Last author DOI 10.1007/s10147-024-02544-w↗
  13. Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Last author DOI 10.1038/s41598-024-73020-8↗
  14. Gastrointestinal: Enlarged pancreatic tail mass during chemotherapy for pancreatic cancer. Last author DOI 10.1111/jgh.16566↗
  15. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. Last author DOI 10.1186/s12885-024-12722-8↗
  16. Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. Last author DOI 10.1007/s00432-023-04966-x↗
  17. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. Last author DOI 10.1186/s12885-023-11205-6↗
  18. Main pancreatic duct dilatation and pancreatic cysts in relatives and spouses of patients with pancreatic cancer. Last author DOI 10.1371/journal.pone.0280403↗
  19. Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Last author DOI 10.3390/cancers15030970↗
  20. Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. Last author DOI 10.1016/j.jgo.2022.07.010↗
  21. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  22. Refractory Lower Limb Edema Resolved by Endovascular Stent Placement for Inferior Vena Cava Stenosis in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002152↗
  23. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… Last author DOI 10.1371/journal.pone.0264653↗
  24. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancr… Co-author DOI 10.3389/fmed.2022.928182↗
  25. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… Last author DOI 10.3390/curroncol29040216↗
  26. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastat… Last author DOI 10.1002/jgh3.12555↗
  27. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Co-author DOI 10.3390/cancers13030502↗
  28. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Last author DOI 10.3390/cancers13184733↗
  29. Effectiveness of Contrast-Enhanced Ultrasonography for the Characterization of Small and Early Stage Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ultrasmedbio.2020.04.016↗
  30. Efficacy of Larger-Diameter Plastic Stent Placement for Preoperative Biliary Drainage in Patients Receiving Neoadjuvant Chemoradiation for Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001509↗
  31. Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy. First author DOI 10.1097/mpa.0000000000001652↗
  32. Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer. Co-author DOI 10.4251/wjgo.v12.i7.768↗
  33. A case of stage IA pancreatic ductal adenocarcinoma accompanied with focal pancreatitis demonstrated by contrast-enhanced ultrasonography. Co-author DOI 10.1007/s10396-018-0870-5↗
  34. Clinical Features and Prognosis of Patients With the Bone Metastasis of Pancreatic Cancer: A Single-Institutional Cohort Study. Co-author DOI 10.1097/mpa.0000000000001098↗
  35. Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barc… First author DOI 10.1371/journal.pone.0192611↗
  36. Risk of peritoneal carcinomatosis by endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Co-author DOI 10.1007/s00535-012-0693-x↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Ikezawa · 31 shared papers, 2013–2026 · strength 5.29
  2. Ryoji Takada · 28 shared papers, 2018–2026 · strength 4.64
  3. Yugo Kai · 20 shared papers, 2021–2026 · strength 3.65
  4. Makiko Urabe · 18 shared papers, 2021–2026 · strength 3.45
  5. Takuo Yamai · 16 shared papers, 2020–2026 · strength 2.41
  6. Yusuke Seiki · 8 shared papers, 2023–2026 · strength 1.65
  7. Hidenori Takahashi · 10 shared papers, 2018–2026 · strength 1.52
  8. Nobuyasu Fukutake · 11 shared papers, 2013–2026 · strength 1.38
  9. Reiko Ashida · 10 shared papers, 2020–2026 · strength 1.35
  10. Ko Watsuji · 7 shared papers, 2023–2026 · strength 1.34
  11. Shigenori Nagata · 8 shared papers, 2018–2026 · strength 1.26
  12. Kana Hosokawa · 4 shared papers, 2025–2026 · strength 0.96
  13. Yasuharu Kawamoto · 6 shared papers, 2022–2024 · strength 0.92
  14. Tatsuya Ioka · 7 shared papers, 2013–2026 · strength 0.80
  15. Kazuma Daiku · 6 shared papers, 2021–2022 · strength 0.79
  16. Kazuhiro Katayama · 8 shared papers, 2018–2021 · strength 0.79
  17. Hirofumi Akita · 5 shared papers, 2018–2026 · strength 0.77
  18. Takumi Kinomoto · 3 shared papers, 2025–2026 · strength 0.71
  19. Yoji Kukita · 4 shared papers, 2018–2026 · strength 0.59
  20. Sachiko Tanaka · 5 shared papers, 2013–2023 · strength 0.52
  21. Junko Fukuda · 4 shared papers, 2018–2023 · strength 0.49
  22. Teruki Teshima · 3 shared papers, 2020–2025 · strength 0.45
  23. Taro Yamashita · 2 shared papers, 2026 · strength 0.41
  24. Kazuo Hara · 2 shared papers, 2026 · strength 0.41
  25. Shinichiro Hasegawa · 2 shared papers, 2022–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.